Učitavanje...
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
We conducted a phase II study of the AKT inhibitor, MK2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma or lymphoblastic lymphoma. MK-2206 was administered orally at 200 mg once weekly in 28-d cycles up to 12 cycles in the absence of progression or sig...
Spremljeno u:
| Izdano u: | Br J Haematol |
|---|---|
| Glavni autori: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5278973/ https://ncbi.nlm.nih.gov/pubmed/26213141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13603 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|